$9.74
1.46% yesterday
Nasdaq, Dec 24, 07:56 pm CET
ISIN
US25056L1035
Symbol
DSGN

Design Therapeutics Inc Stock price

$9.74
+1.10 12.73% 1M
+5.77 145.34% 6M
+3.57 57.86% YTD
+3.39 53.39% 1Y
+0.21 2.20% 3Y
-10.26 51.30% 5Y
-10.26 51.30% 10Y
-10.26 51.30% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.14 1.46%
ISIN
US25056L1035
Symbol
DSGN
Industry

Key metrics

Basic
Market capitalization
$554.8m
Enterprise Value
$348.9m
Net debt
positive
Cash
$206.0m
Shares outstanding
57.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
96.0%
Return on Equity
-20.7%
ROCE
-38.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-77.4m | $-107.4m
EBIT
$-78.0m | $-84.0m
Net Income
$-67.5m | $-74.2m
Free Cash Flow
$-52.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.4% | -75.0%
EBIT
-29.2% | -35.5%
Net Income
-40.9% | -48.4%
Free Cash Flow
-12.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.2
FCF per Share
$-0.9
Short interest
5.6%
Employees
57
Rev per Employee
$0.0
Show more

Is Design Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Design Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Design Therapeutics Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Design Therapeutics Inc forecast:

Buy
78%
Hold
22%

Financial data from Design Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
14% 14%
-
- Research and Development Expense 58 58
34% 34%
-
-77 -77
29% 29%
-
- Depreciation and Amortization 0.62 0.62
7% 7%
-
EBIT (Operating Income) EBIT -78 -78
29% 29%
-
Net Profit -67 -67
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Design Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Design Therapeutics Inc Stock News

Neutral
GlobeNewsWire
29 days ago
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Positive
24/7 Wall Street
about one month ago
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.
Neutral
GlobeNewsWire
about 2 months ago
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy  (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design ...
More Design Therapeutics Inc News

Company Profile

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.

Head office United States
CEO Pratik Shah
Employees 57
Founded 2017
Website www.designtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today